Elizabeth D. Cash, PhD, on Addressing the Psychological Aspects of Head and Neck Cancer
2022 Multidisciplinary Head and Neck Cancers Symposium
Elizabeth D. Cash, PhD, of the University of Louisville, discusses depression among patients with head and neck cancer, the impact it can have on prognosis, and the importance of helping patients cope through screening for depressive symptoms and treatment with collaborative care models.
Nancy Lee, MD, of Memorial Sloan Kettering Cancer Center, discusses results from the 30ROC trial, which showed that intratreatment FMISO [(18)F-fluoromisonidazole] PET response could identify patients with human papillomavirus–positive oropharyngeal carcinoma who may be sensitive to radiation therapy. Based on this information, researchers were able to de-escalate radiotherapy to 30 Gy from the standard 70 Gy, in the setting of chemotherapy (Keynote II).
Peter Zeng, MD/PhD Candidate, at Ontario’s Western University, discusses a three-gene prognostic classifier tool, known as UWO3, which was validated in six external cohorts and shown to identify patients with human papillomavirus–related head and neck cancer that is likely to recur following aggressive radiation de-escalation.
Sue S. Yom, MD, PhD, of the University of California, San Francisco, discusses some of the latest developments in thyroid cancer, including the mutational landscape, therapies for high-risk and anaplastic diseases, and multimodalities for aggressive differentiated thyroid cancers.
Michelle Mierzwa, MD, of the University of Michigan, discusses early findings from a phase II trial of FDG-PET (fluorodeoxyglucose–positron-emission tomography) de-escalated radiotherapy for patients with p16-positive orophyaryngeal cancer. An interim analysis suggests that for approximately half of patients with stage I or II disease, this type of treatment may decrease toxicity and improve quality of life.
David S. Hong, MD, of The University of Texas MD Anderson Cancer Center, discusses results from a phase II cohort, which suggest favorable antitumor activity with tisotumab vedotin-tftv in patients with head and neck squamous cell carcinoma that has progressed after treatment with a platinum-containing regimen. Additional research is warranted, says Dr. Hong, in the second-line setting as well as in treatment-naive patients in combinations with pembrolizumab and carboplatin.